RXO $355 million notes offering
The notes are being offering in connection with the intended spinoff of RXO
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Immatics $110 million follow-on offering
We advised Immatics on the offering of shares
Solid Biosciences $75 million common stock PIPE offering
The financing is taking place concurrently with the company’s acquisition of AavantiBio
Alignment Healthcare $132.75 million secondary offering
The shares are listed on the Nasdaq Global Select Market
Immunocore $250 million at-the-market offering
The ADSs are listed on the Nasdaq Global Market
Assertio $70 million convertible senior notes offering
The 6.5% notes are due 2027
ADC Therapeutics $175 million term loan facility and other financings
We advised the company on the new facility, a $115 million exchange and a $6.25 million share sale
Terns Pharmaceuticals $65 million common stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
Precigen sale of Trans Ova Genetics to URUS
We are advising Precigen on the transaction
Gracell Biotechnologies at-the-market offering
The ADSs are listed on the Nasdaq Global Select Market